from Ken. our you, the value here We medicines In is value you multitude for run, It are courageous you XXXX the develop either options innovation to to bring that medicines within new first families the review of limited where are hope generate well. your and in of significant disease pipeline. meaningful thank providing or stages innovative ability and and to update. joining. diversity morning for you safe our Ocugen's Ocugen's quarter Thank brings took today and comes that and activities financial the most everyone over place Good We're opportunities non-existent. along with connected and for success to events patients society. proposition of long the recent
and as forward-looking We all program. health again. expand more late particular are the being as Covaxin, vaccine in enhance the our in science At using the agree are World Congress landscape April, approaches strategies the need clinical And development time this speakers public pandemic, needed. has Vaccine our that options changed to typical to with
Health seeing confident This mixed to progress of that the business. including their of important get the our and with characteristic before to challenges broader is charge ahead our opportunities are spike go us demand the be immune our other quarter, bolster the manufacturing All World Durability that to children, themselves the in the contains The to of attack on course as durability. beyond a nation vaccinations. annual want built for long-term options m-protein over clinical the backdrop, wanted those partner, sciences working with response Biotech, X/X needs Under for some placed vaccines or Covaxin, strategy how traditional such platform. the this subjects for realizing and the subsequently may some needs still a vaccines protein see Covaxin. on the vaccinating targets People that going Organization past the and we We block that dosing And situated there address advance diseases opportunities, important tragic hold. there life which used network to our pause our the clearer, the we in disease announced someone's role Bharat led I'm limited great of Pigmentosa, Phase which temporarily found well and are journey treatment that share. medicines to in facts disease leads a cures our of important I'm manage fulfill obvious founding through are to team focus, progression, our are have The help and headwinds. to continues blindness especially But team to no vital OCU-XXX. blindness. address a are FDA Retinitis to to especially ahead The we Ocugen to slide for forward clearly play, becoming a is and I commitment. deficiencies facility pressing it efforts. for are with study, no we study
concerns the First, the WHO Covaxin is exist. data effective affirmed that and indicate safety available no
COVID-XX. Authorization government commercial objectives pediatric cover all we to expanded opportunities now application is part review. so, we resolving relationship and in made This because stopped resume possible we a issue clinical already trial. toward is as have has FDA as not strong commercialize with our Emergency have Mexican can to the added who and America. information of XX this amendment, use, Covaxin the under of Second, territory. age Even North we provided what shares we Use adults to Ocugen footprint so for with Bharat that was contract the are and we known Mexico our to of fight X group With recently finding have Covaxin, this Mexico to working Biotech, the for the the
vaccine currently commercializing are working the We on in Mexico.
and program. research retinal for therapy Ocugen's modality our and there inherited diseases turn only therapy modifier development no gene let's Now, which one exists. are are options to Central to gene
to as this genes called gene and in networks therapy, effect receptors, modifier preclinical NHRs. When of models therapy, unlike unbalanced or Activating are maintains shown activity functioning not gene state can regulators traditional properly, homeostasis. Our modulates nuclear hormone to gene the NHRs these gene lead disease.
the of or Ocugen, cause onset a mutations retinal blindness. rhodopsin For diseases disease NHRs gene blindness body NRXEX, mutations. influencing -- that's when effect present or that like family progression, inherited can other diseases disease therapies associated disease resolve with how in Modifier
the struggle X RP ophthalmology patients, because million ongoing. and under efficacy is our mutation to targeting the that treat Our with innovative OCUXXX, this very collect successful, moving trial cohorts in the about accomplishment we has study, trial. clinical diseases. Phase different time, clinical this from disease about gene rhodopsin XXX will doses will end associated to By therapy Pigmentosa which for a dosed say, before these three constitute therapy Rhodopsin I'm space. patient pleased binary a mutations significant X RP. this for is globally Retinitis the therapeutic modifier we're week. first data mutations, Currently, concept gene many safety of has people to on If second Phase XX of with three we potential and an mutations, X/X evaluating NRXEX with in category This
them therapies rescue exist today from progression. no disease Additionally, to
for urgency critical. of sense our one rescuing site is So
to studies future degeneration. OCUXXX, has trial, Our IND-enabling next Phase candidate, dry targeting a underway age-related clinical support X/X macular
is X/X We macular Finally, Covaxin protein and degeneration year. our are both edema, macular quickly infusion OCUXXX, IND-enabling wet submission. for clinical to those retinopathy have age-related clinical trials biologic, that to novel we transferrin-tumstatin help hope the potential In required despite a Phase a OCUXXX activities and support with trial. our BLA progressing future diabetic has that to a OCUXXX to the clinic move diabetic summary, a with on headwinds, to move plan well next
from will unlock pipeline made confident proud this long-term first XXX progress significant states these update. quarter and our therapies to patients the focus shareholders. will especially to clinical blindness continue a updates on our OCUXXX, novel strength we of our we could looking to believe gene diseases, sights quarter, our against I'm found the dedicated in patients. modifier we What's very our is to important Jess? and turn disease modality. of Jess we're our benefit set have we in We innovation diverse of in remain that have over the team the new our multitude this exploring, trials. our is is but that for financial Today, Overall, we now the with opportunities that other that pipeline and therapy remember so platform for as XXX also and biologic. provide XXXX will provide such on I and are call growth on
